{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=11", "query": { "intervention": "Placebo SC Injection", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 833, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T13:26:59.811Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02192190", "title": "A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis, Knee" ], "interventions": [ { "name": "LY2951742", "type": "DRUG" }, { "name": "Placebo- oral", "type": "OTHER" }, { "name": "Placebo - SC", "type": "OTHER" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 268, "start_date": "2014-07", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Anaheim, California • San Diego, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192190" }, { "nct_id": "NCT06072157", "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants", "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "AK006-IV", "type": "DRUG" }, { "name": "Placebo-IV", "type": "DRUG" }, { "name": "AK006-SC", "type": "DRUG" }, { "name": "Placebo-SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 136, "start_date": "2023-08-28", "completion_date": "2025-05-12", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 19, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072157" }, { "nct_id": "NCT05421598", "title": "Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 437, "start_date": "2022-06-30", "completion_date": "2025-03-20", "has_results": true, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • San Jose, California + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05421598" }, { "nct_id": "NCT05552157", "title": "A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Remternetug (SC)", "type": "DRUG" }, { "name": "Matching Placebo (Remternetug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2024-11-22", "completion_date": "2034-08-30", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 13, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552157" }, { "nct_id": "NCT02552212", "title": "Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthritis", "Nonradiographic Axial Spondyloarthritis", "Nr-axSpA" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2015-09", "completion_date": "2020-05", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552212" }, { "nct_id": "NCT07795164", "title": "Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metabolic Dysfunction-Associated Steatohepatitis (MASH)" ], "interventions": [ { "name": "Pemvidutide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Altimmune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1800, "start_date": "2026-07-30", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 9, "location_summary": "North Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 6 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Gardena", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07795164" }, { "nct_id": "NCT05724199", "title": "A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Rocatinlimab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 746, "start_date": "2023-02-21", "completion_date": "2024-12-04", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05724199" }, { "nct_id": "NCT07224399", "title": "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healhty", "Overweight or Obesity" ], "interventions": [ { "name": "BGM1812", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2025-10-09", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224399" }, { "nct_id": "NCT05068284", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "ABBV-154", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 176, "start_date": "2022-01-31", "completion_date": "2023-07-20", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 45, "location_summary": "Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05068284" }, { "nct_id": "NCT01959971", "title": "Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2013-12", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-10-30T13:26:59.811Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959971" } ] }